1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (011) 81-942-34-2623
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Review Article
You have full text access to this OnlineOpen article
Hepatocellular carcinoma: Is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?
Article first published online: 25 JUN 2003
DOI: 10.1002/cncr.11576
Copyright © 2003 American Cancer Society
Additional Information
How to Cite
Koga, H. (2003), Hepatocellular carcinoma: Is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?. Cancer, 98: 661–667. doi: 10.1002/cncr.11576
Publication History
- Issue published online: 1 AUG 2003
- Article first published online: 25 JUN 2003
- Manuscript Accepted: 12 MAY 2003
- Manuscript Revised: 5 MAY 2003
- Manuscript Received: 21 OCT 2002
- Abstract
- Article
- References
- Cited By
Keywords:
- hepatitis C virus (HCV);
- cyclooxygenase-2 (COX-2);
- hepatocellular carcinoma (HCC);
- chemoprevention;
- angiogenesis;
- retinoid;
- peroxisome proliferator-activated receptor
Abstract
Inhibitors of cyclooxygenase-2 (COX-2) have proapoptotic and antiangiogenic effects on malignant tumors and inhibit their invasion to surrounding tissues. These properties are derived from COX-dependent and/or COX-independent signaling via peroxisome proliferator-activated receptor γ. Although the role of COX-2 involvement in human hepatocarcinogenesis has not been determined yet, selective COX-2 inhibitors with COX-independent properties may potentially suppress hepatocarcinogenesis. This hypothesis should be confirmed in in vivo studies using animal models. These studies may provide insights into any application of the COX-2 inhibitor for primary and/or secondary chemoprevention. Cancer 2003;98:661–7. © 2003 American Cancer Society.
DOI 10.1002/cncr.11576